The Expression of ESR1 Gene in Paraffin Tissue Blocks of Women with Breast Cancer

Document Type : Original Article (s)

Authors

1 Department of Biology, School of Basic Sciences, Islamic Azad University, East Tehran Branch, Tehran, Iran

2 Assistant Professor, Department of Biology, School of Basic Sciences, Islamic Azad University, East Tehran Branch, Tehran, Iran

3 Young Researchers and Elite Club, Islamic Azad University, East Tehran Branch, Tehran, Iran

Abstract

Background: Breast cancer is the most common malignant tumor and cause of cancer death in women. Some biomarkers are used to estimate the response to therapy. One of the most common indicators is estrogen receptors (ER). It seems that there is a significant correlation between receptor existence (ER +) and risk of breast cancer. This study aimed to measurement the estrogen receptor alpha expression in women with breast cancer. Methods: In this study, 20 cancerous paraffin-embedded tissue blocks from patients with breast cancer and 10 non-cancerous were collected. After deparaffinization, RNA was extracted with RNX Plus solution. Complementary DNA (cDNA) was synthesized via reverse transcription reaction using Moloney murine leukemia virus (MMULV) enzyme. Estrogen receptors gene expression was measured using relative real-time polymerase chain reaction (real-time PCR) reaction. In this study, glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was used as internal control gene.Findings: Estrogen receptor alpha expression in cancerous tissues had significant over-expression compared to normal tissues. Also, increasing the stage of disease, expression of estrogen receptor alpha was increased (P < 0.0001).Conclusion: According to the results, it can be concluded that the estrogen receptor alpha gene expression strongly increases in tumor samples. So, determination of estrogen receptor alpha expression can be used as indicator agent for response to treatment and follow-up. 

Keywords

References

  1. International Agency for Research on cancer. Cancer mondial [Online]. [cited 2006 Dec 7]; Available from: URL:http://www-dep.iarc.fr
  2. Iranian Center for Prevention and Control of Disease, Center of Disease Management, Ministry of Health and Medical Education. Summary report on cancer incidence in Iran. Tehran, Iran: Ministry of Health and Medical Education: 2000.
  3. Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev 2004; 5(1): 24-7.
  4. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene 2006; 25(43): 5898-905.
  5. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447(7148): 1087-93.
  6. Noori-Daloii MR. Medical molecular genetics in the 3rd millennium. Tehran, Iran: Samer Publications; 2009.
  7. Shao W, Brown M. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 2004; 6(1): 39-52.
  8. Foidart JM, Colin C, Denoo X, Desreux J, Beliard A, Fournier S, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998; 69(5): 963-9.
  9. Amend K, Hicks D, Ambrosone CB. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res 2006; 66(17): 8327-30.
  10. Shyamala G, Chou YC, Cardiff RD, Vargis E. Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. Cancer Res 2006; 66(21): 10391-8.
  11. DeVita VT, Lawrence TS, Rosenberg SA. Cancer: principles and practice of oncology-advances in oncology. Philadelphia, PA: Lippincott Williams and Wilkins; 2010.
  12. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res 2007; 13(7): 1950-4.
  13. Rosai J. Rosai and Ackerman's surgical pathology. New York, NY: Mosby; 2004.
  14. Harris JR, Lippman ME, Osborne CK, Morrow M. Diseases of the breast. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2011.
  15. Noori-Daloii MR, Tabarestani S. Molecular genetics, diagnosis and treatment of breast cancer: review article. J Sabzevar Univ Med Sci 2000; 17(2): 74-87. [In Persian].
  16. Balducci L. Management of cancer in the elderly. Oncology (Williston Park) 2006; 20(2): 135-43.
  17. Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol 2008; 66(1): 65-74.
  18. Bieche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 2001; 20(56): 8109-15.
  19. de Cremoux P, Tran-Perennou C, Elie C, Boudou E, Barbaroux C, Poupon MF, et al. Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays. Biochem Pharmacol 2002; 64(3): 507-15.
  20. Suzuki T, Miki Y, Moriya T, Shimada N, Ishida T, Hirakawa H, et al. Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. Cancer Res 2004; 64(13): 4670-6.
  21. Lopez-Tarruella S, Schiff R. The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clin Cancer Res 2007; 13(23): 6921-5.
  22. Ariazi EA, Ariazi JL, Cordera F, Jordan VC. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006; 6(3): 181-202.
  23. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472): 1687-717.
  24. Yamashita H. Current research topics in endocrine therapy for breast cancer. Int J Clin Oncol 2008; 13(5): 380-3.
Journal of Isfahan Medical School
Volume 32, Issue 317 - Serial Number 317
November and December 2015
Pages 2324-2332

Files

History

  • Receive Date: 02 December 2014
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics